SA
RCKT icon

Sovran Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Sovran Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-196,028
Closed -$580K – 543
2025
Q2 		$580K Sell
196,028
-127,063
-39% -$644K 0.06% 293
2025
Q1 		$2.05M Buy
323,091
+172,324
+114% +$1.7M 0.27% 96
2024
Q4 		$1.57M Buy
+150,767
New +$2.27M 0.22% 108

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Sovran Advisors's RCKT Position: Q3 2025 in Review

Sovran Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 196,028 shares — an estimated $580K sold.

Sovran Advisors first reported a position in RCKT in Q4 2024 and held it in 3 quarters. The position peaked at $2.05M in Q1 2025. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Sovran Advisors reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sovran Advisors sold 196,028 Rocket Pharmaceuticals shares in Q3 2025, an estimated $580K.
  • Sovran Advisors first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Sovran Advisors's Rocket Pharmaceuticals position peaked at $2.05M in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Sovran Advisors's 13F filing for Q3 2025, filed 31 Oct 2025.